Gastroenterology Practice Questions

Q: A 22-year-old woman presents with chronic diarrhea. She has no abdominal discomfort, feels well, and reports no weight loss or systemic symptoms. Physical examination reveals a healthy young woman who is 5'7" tall and weighs 170 lb. The complete physical examination is normal. Which of the following is the most likely cause of a secretory diarrhea in this young woman?

Surreptitious use of stimulant laxatives. The clinical presentation describes a young woman with **chronic secretory diarrhea** who is otherwise healthy, asymptomatic (no pain or weight loss), and has a normal physical examination. In young patients, especially those without systemic signs of illness, **surreptitious laxative abuse** (Factitious Diarrhea) is a common cause of chronic secretory diarrhea. Stimulant laxatives (e.g., bisacodyl, senna) increase intestinal secretion and motility, leading to high-volume watery stools that persist even during fasting. **Analysis of Options:** * **A. Surreptitious use of stimulant laxatives (Correct):** This is often seen in patients with underlying psychological stressors or eating disorders. The absence of weight loss and abdominal pain in a "healthy-looking" patient is a classic clue. * **B. Carcinoid tumor:** While it causes secretory diarrhea, it is usually associated with the "Carcinoid triad" (flushing, wheezing, and right-sided heart valves) and systemic symptoms, which are absent here. * **C. Ulcerative colitis:** This typically presents with **inflammatory diarrhea**, characterized by blood, mucus, tenesmus, and abdominal cramping. * **D. Lactose deficiency:** This causes **osmotic diarrhea**. A key feature is that the diarrhea improves or resolves with fasting (unlike secretory diarrhea) and is associated with bloating and flatulence. [1] **NEET-PG High-Yield Pearls:** * **Secretory vs. Osmotic Diarrhea:** Secretory diarrhea has a **low stool osmotic gap ( 125 mOsm/kg)** and stops with fasting. * **Diagnosis of Laxative Abuse:** Suspect in "medical-adjacent" professionals or young women. Diagnosis is confirmed by a **stool laxative screen** or finding **melanosis coli** (dark pigmentation of the colon) on colonoscopy (specific to anthraquinone laxatives like senna).

Q: What is the classification system used for Barrett's esophagus?

Prague. **Explanation:** The **Prague C & M Criteria** is the internationally recognized classification system used to standardize the endoscopic assessment of **Barrett’s Esophagus (BE)**. It relies on two primary measurements: 1. **C (Circumferential):** The length of the esophagus where the entire circumference is lined by columnar epithelium. 2. **M (Maximal):** The maximum length of the columnar-lined esophagus, including any proximal tongues or islands. These measurements are taken from the gastroesophageal junction (top of the gastric folds) to the proximal extent of the metaplastic change. This system provides high inter-observer reliability, which is crucial for monitoring disease progression and response to therapy. **Analysis of Incorrect Options:** * **McCormack:** This classification is used to grade the severity of **Portal Hypertensive Gastropathy (PHG)** based on endoscopic appearance (e.g., snake-skin pattern). * **Tanoue:** This is a classification system for **Esophageal Varices**, specifically focusing on the tortuosity and color of the vessels. * **Amsterdam:** These are criteria used to identify families at high risk for **Lynch Syndrome** (Hereditary Non-Polyposis Colorectal Cancer - HNPCC). **High-Yield Clinical Pearls for NEET-PG:** * **Definition of BE:** Intestinal metaplasia (presence of **Goblet cells**) of the lower esophagus [1]. * **Histology:** Squamous epithelium is replaced by Columnar epithelium [1]. * **Surveillance:** Patients with BE require periodic endoscopy with the **Seattle Protocol** (4-quadrant biopsies every 1–2 cm) to screen for dysplasia or adenocarcinoma. * **Risk Factor:** Chronic GERD is the primary driver; BE increases the risk of **Esophageal Adenocarcinoma** by 30-40 times [1].

Q: Raised gastrin level without an associated increase in acid secretion is seen in which of the following conditions?

Pernicious anemia. ### Explanation The correct answer is **Pernicious Anemia**. #### 1. Why Pernicious Anemia is Correct The physiological regulation of gastrin follows a negative feedback loop: high gastric acid (low pH) inhibits gastrin release, while low gastric acid (high pH) stimulates it [1]. In **Pernicious Anemia**, autoimmune destruction of gastric parietal cells [2] leads to **achlorhydria** (absence of HCl). The lack of acid removes the inhibitory feedback on G-cells in the antrum, resulting in **reactive hypergastrinemia** [1]. Thus, you see high gastrin levels with low/absent acid secretion. #### 2. Why Other Options are Incorrect * **Gastrinoma (Zollinger-Ellison Syndrome):** This is a gastrin-secreting tumor. It causes high gastrin levels which *directly* stimulate parietal cells to produce **massive amounts of acid**, leading to severe peptic ulcers [1]. * **G-cell Hyperplasia:** This involves an increased number of G-cells, leading to excessive gastrin production and a subsequent **increase in acid secretion** (mimicking ZES). * **Carcinoma Stomach:** While some gastric cancers (like those in the antrum) might decrease acid if they destroy parietal cell mass, they do not classically present with the profound hypergastrinemia seen in primary achlorhydric states like pernicious anemia. #### 3. NEET-PG High-Yield Pearls * **Hypergastrinemia with High Acid:** Gastrinoma (ZES), G-cell hyperplasia, Retained antrum syndrome, Gastric outlet obstruction. * **Hypergastrinemia with Low Acid:** Pernicious anemia (Type A Gastritis), Long-term PPI use, Atrophic gastritis [1]. * **Secretin Stimulation Test:** This is the gold standard to differentiate ZES from other causes of high gastrin. In ZES, gastrin levels **rise** after secretin injection; in other conditions, gastrin levels fall or remain stale. * **Pernicious Anemia Triad:** Megaloblastic anemia + Achlorhydria + Vitamin B12 deficiency (due to lack of Intrinsic Factor).

Q: Which of the following is excluded from the criteria for diagnosing acute pancreatitis?

Cullen's sign. The diagnosis of acute pancreatitis is based on the **Revised Atlanta Criteria (2012)**. To establish a diagnosis, at least **two of the following three** criteria must be met: 1. **Clinical:** Acute onset of persistent, severe, epigastric pain often radiating to the back [1]. 2. **Biochemical:** Serum amylase and/or lipase levels ≥3 times the upper limit of normal. 3. **Radiological:** Characteristic findings of acute pancreatitis on contrast-enhanced computed tomography (CECT), MRI, or transabdominal ultrasound [1]. **Why Cullen’s Sign is the correct answer:** While **Cullen’s sign** (periumbilical ecchymosis) and **Grey Turner’s sign** (flank ecchymosis) are classic physical exam findings associated with hemorrhagic pancreatitis, they are **not** part of the formal diagnostic criteria. These signs are non-specific (can occur in ruptured ectopic pregnancy or AAA) and typically appear late, making them poor diagnostic markers. **Analysis of Incorrect Options:** * **Option A & B:** These represent the clinical and biochemical pillars of the Atlanta Criteria. Lipase is generally preferred over amylase due to its higher sensitivity and longer half-life. * **Option D:** Imaging is the third pillar. Note that if the first two criteria are met, imaging is often not required for initial diagnosis [1] but is used to assess complications or if the diagnosis is uncertain. **High-Yield Clinical Pearls for NEET-PG:** * **Serum Lipase** is more specific and remains elevated longer (7–14 days) than amylase. * The **degree of enzyme elevation** does not correlate with the severity of the disease. * **Most common cause:** Gallstones (Global/India), followed by Alcohol. * **Drug-induced causes:** Azathioprine, Valproate, Thiazides, and Estrogens.

Q: Antiendomysial antibody is used in the screening of which condition?

Coeliac disease. **Explanation:** **Coeliac Disease (Correct Answer):** Anti-endomysial antibody (EMA) is a highly specific serological marker for Coeliac disease [1]. It is an IgA-class antibody directed against **tissue transglutaminase (tTG)** located in the endomysium (the connective tissue sheath surrounding muscle fibers) [1]. * **Gold Standard Screening:** While **IgA anti-tTG** is the preferred initial screening test due to its high sensitivity and lower cost, **IgA Anti-endomysial antibody** has a specificity approaching 100%, making it excellent for confirming a positive screening result before proceeding to a small bowel biopsy. **Incorrect Options:** * **Myasthenia Gravis:** Characterized by antibodies against **acetylcholine receptors (AChR)** or muscle-specific kinase (MuSK) at the neuromuscular junction. * **Autoimmune Hepatitis:** Associated with **Anti-nuclear antibodies (ANA)** and **Anti-smooth muscle antibodies (ASMA)** in Type 1, and **Anti-liver kidney microsomal-1 (LKM-1)** antibodies in Type 2 [2]. * **Graves Disease:** Caused by **Thyroid-stimulating immunoglobulin (TSI)** which acts as an agonist to the TSH receptor. **High-Yield Clinical Pearls for NEET-PG:** 1. **Total IgA levels** must be checked alongside Coeliac serology. If a patient is IgA deficient (common in Coeliac), IgA-based tests (EMA/tTG) will be falsely negative; in such cases, **IgG-based tests** (IgG-tTG or IgG-DGP) should be used. 2. **HLA Association:** Coeliac disease is strongly associated with **HLA-DQ2** (95%) and **HLA-DQ8** [1]. 3. **Biopsy Finding:** The characteristic histological feature is **villous atrophy**, crypt hyperplasia, and increased intraepithelial lymphocytes (Marsh Classification) [1]. 4. **Dermatitis Herpetiformis:** The pathognomonic skin manifestation of Coeliac disease, showing granular IgA deposits on skin biopsy.

Q: Which of the following statements about peptic ulcer disease is true?

The incidence of complications has remained unchanged.. ### Explanation **Correct Option: B. The incidence of complications has remained unchanged.** While the overall incidence of Peptic Ulcer Disease (PUD) has significantly declined due to effective *H. pylori* eradication and the widespread use of Proton Pump Inhibitors (PPIs), the incidence of **complications** (such as perforation and hemorrhage) has remained relatively stable. This is primarily attributed to the increasing use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and low-dose aspirin among the aging population, which offsets the gains made by treating *H. pylori* [1]. **Analysis of Incorrect Options:** * **Option A:** *H. pylori* eradication **decreases** the likelihood of complications. It is the most effective strategy to prevent ulcer recurrence and subsequent bleeding or perforation [1]. * **Option C:** In developing countries like India, the reinfection rate of *H. pylori* is **high** (often >2% per year) due to overcrowding, poor sanitation, and contaminated water sources, unlike the low rates (<1%) seen in developed nations. * **Option D:** *H. pylori* eradication **dramatically alters** the recurrence ratio. Without eradication, ulcer recurrence rates are 60–90%; after successful eradication, this drops to <10% [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Most common complication of PUD:** Upper GI Bleed (Hematemesis/Melena) [1]. * **Most common site of perforation:** Anterior wall of the duodenum [1]. * **H. pylori Association:** Strongly linked to Duodenal Ulcers (90-95%) more than Gastric Ulcers (70-80%) [1]. * **Investigation of Choice:** Upper GI Endoscopy (UGIE). * **Gold Standard for H. pylori diagnosis:** Endoscopic biopsy followed by Histopathology (though Urease Breath Test is the best non-invasive test for confirming eradication) [1].

Q: A 30-year-old patient has persistent antibodies to HCV for 6 months with normal AST/ALT levels and no symptoms or stigmata of liver disease. What is the most appropriate next step in management?

Determine HCV RNA levels. ### Explanation The presence of **HCV antibodies (Anti-HCV)** indicates that the patient has been exposed to the Hepatitis C virus at some point. However, it does not distinguish between an active (chronic) infection and a resolved past infection [1]. **1. Why Option D is Correct:** In Hepatitis C, approximately 15–25% of patients clear the virus spontaneously but remain antibody-positive for life [1]. Furthermore, chronic HCV infection is often "clinically silent," where patients may have **persistently normal ALT/AST levels** despite ongoing viral replication and progressive liver fibrosis [1]. Therefore, the presence of antibodies must always be followed by a **qualitative or quantitative HCV RNA test (PCR)** to confirm active viremia [1]. If HCV RNA is detected, the patient has chronic hepatitis C and requires treatment, regardless of enzyme levels. **2. Why Other Options are Incorrect:** * **Option A & B:** Reassurance or simply repeating antibody titers is inappropriate because the patient may have active, transmissible chronic infection that can lead to cirrhosis or HCC if left untreated. Antibody titers do not correlate with disease activity. * **Option C:** Normal liver enzymes are not a reliable indicator of viral clearance. Up to 30% of patients with chronic HCV have normal ALT levels. Relying on enzymes alone would miss a significant number of chronic cases. **Clinical Pearls for NEET-PG:** * **Screening Test:** Anti-HCV (ELISA). * **Confirmatory/Gold Standard for Active Infection:** HCV RNA by PCR [1]. * **Treatment Goal:** Sustained Virologic Response (SVR), defined as undetectable HCV RNA 12–24 weeks after completing antiviral therapy. * **High-Yield Fact:** Unlike Hepatitis B, Hepatitis C does not integrate into the host genome; therefore, it is potentially curable with Direct-Acting Antivirals (DAAs).

Q: All of the following are true for patients with ulcerative colitis associated with primary sclerosing cholangitis (PSC), EXCEPT:

PSC reverses after a total colectomy.. The correct answer is **D**. The underlying medical concept is that **Primary Sclerosing Cholangitis (PSC)** follows a clinical course independent of the underlying **Ulcerative Colitis (UC)** [2]. While approximately 70-80% of PSC patients have UC [3], performing a total colectomy (which is curative for the intestinal symptoms of UC) does not halt, reverse, or prevent the progression of PSC or the risk of associated biliary malignancies. **Analysis of Options:** * **Option A (Biliary Cirrhosis):** True. PSC is a chronic cholestatic disease characterized by progressive inflammation and fibrosis of the intrahepatic and extrahepatic bile ducts. This leads to "beading" on imaging and eventually results in secondary biliary cirrhosis and liver failure. * **Option B (Raised Alkaline Phosphatase):** True. A cholestatic pattern of liver enzymes is the hallmark of PSC. An elevated serum alkaline phosphatase (ALP) is often the first biochemical abnormality detected, even in asymptomatic patients [1]. * **Option C (Hilar Cholangiocarcinoma):** True. Patients with PSC have a significantly increased lifetime risk (up to 10-15%) of developing cholangiocarcinoma, most commonly at the biliary confluence (Klatskin tumor/hilar type). **NEET-PG High-Yield Pearls:** * **Gold Standard Diagnosis:** MRCP (shows "string of beads" appearance). Liver biopsy shows pathognomonic **"onion-skin" fibrosis**. * **Antibody:** p-ANCA is positive in 60-80% of cases [1], [3]. * **Cancer Risks:** PSC increases the risk of both **Cholangiocarcinoma** and **Colorectal Cancer** (more so than UC alone). * **Treatment:** Liver transplantation is the only definitive treatment for end-stage PSC; medical therapies like Ursodeoxycholic acid (UDCA) improve biochemistry but not survival.

Question 1

A 22-year-old woman presents with chronic diarrhea. She has no abdominal discomfort, feels well, and reports no weight loss or systemic symptoms. Physical examination reveals a healthy young woman who is 5'7" tall and weighs 170 lb. The complete physical examination is normal. Which of the following is the most likely cause of a secretory diarrhea in this young woman?

Accepted Answer

Surreptitious use of stimulant laxatives

Answer

Carcinoid tumor

Answer

Ulcerative colitis

Answer

Lactose deficiency

Question 2

What is the classification system used for Barrett's esophagus?

Accepted Answer

Prague

Answer

McCormack

Answer

Tanoue

Answer

Amsterdam

Question 3

Raised gastrin level without an associated increase in acid secretion is seen in which of the following conditions?

Accepted Answer

Pernicious anemia

Answer

Carcinoma stomach

Answer

Gastrinoma

Answer

G cell hyperplasia

Question 4

A patient complains of chronic constipation. Despite increasing dietary fiber on his physician's advice, the constipation persists. After referral to a gastroenterologist, colonoscopy reveals over fifty 2-3 mm openings into the bowel mucosa. The intervening mucosa appears normal, and no bleeding is observed. Which of the following is the most likely diagnosis?

Accepted Answer

Diverticulosis

Answer

Amebiasis

Answer

Crohn disease

Answer

Pseudomembranous colitis

Question 5

Which of the following is excluded from the criteria for diagnosing acute pancreatitis?

Accepted Answer

Cullen's sign

Answer

Typical epigastric abdominal pain

Answer

Threefold elevation in serum amylase levels

Answer

Imaging findings suggestive of pancreatitis

Question 6

Antiendomysial antibody is used in the screening of which condition?

Accepted Answer

Coeliac disease

Answer

Myasthenia gravis

Answer

Autoimmune hepatitis

Answer

Graves disease

Question 7

A 52-year-old alcoholic male develops chronic severe upper abdominal pain and maldigestion. Ultrasound studies demonstrate pancreatic calcifications. Which of the following disorders will this patient most likely develop?

Accepted Answer

Diabetes mellitus

Answer

Hyperthyroidism

Answer

Hypothyroidism

Answer

Pheochromocytoma

Question 8

Which of the following statements about peptic ulcer disease is true?

Accepted Answer

The incidence of complications has remained unchanged.

Answer

Helicobacter pylori eradication increases the likelihood of occurrence of complications.

Answer

The incidence of Helicobacter pylori reinfection in India is very low.

Answer

Helicobacter pylori eradication does not alter the recurrence ratio.

Question 9

A 30-year-old patient has persistent antibodies to HCV for 6 months with normal AST/ALT levels and no symptoms or stigmata of liver disease. What is the most appropriate next step in management?

Accepted Answer

Determine HCV RNA levels

Answer

Reassure the patient

Answer

Repeat antibody titre every three years

Answer

Repeat liver enzymes every year

Question 10

All of the following are true for patients with ulcerative colitis associated with primary sclerosing cholangitis (PSC), EXCEPT:

Accepted Answer

PSC reverses after a total colectomy.

Answer

They may develop biliary cirrhosis.

Answer

May have a raised alkaline phosphatase.

Answer

Increased risk of hilar cholangiocarcinoma.

Gastroenterology — MCQs

Gastroenterology — MCQs

On this page

Practice by Chapter

Want unlimited practice?